Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. - Wikidata - wikimedia - TriplyDB

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

http://www.wikidata.org/entity/Q33371986

about

Role of systemic chemotherapy in urothelial urinary bladder cancer Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma Bladder cancer in the elderly patient: challenges and solutions Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer Systemic therapy for bladder cancer finally comes into a new age.Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy.Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.Recent advances in treatment of advanced urothelial carcinoma.Systemic therapy in bladder cancer Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Systemic therapy for bladder cancer - a medical oncologist's perspective.First- and second-line therapy for metastatic urothelial carcinoma of the bladder Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.Novel agents for advanced bladder cancer.Current therapeutic strategies for invasive and metastatic bladder cancer.Chemotherapy in advanced bladder cancer: current status and future Metastatic bladder cancer: a review of current management The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).Conditional Survival in de novo Metastatic Urothelial Carcinoma Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).Personalized therapy for urothelial cancer: review of the clinical evidence.Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma Novel therapies in genitourinary cancer: an update.Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.Novel strategies for treating relapsed/refractory urothelial carcinoma.Systemic therapy for metastatic urothelial carcinoma.Current optimal chemotherapy for advanced urothelial cancer.Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis.Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium.

P2860

Q27010323-D45D6892-AFC2-47DF-8224-610CF567ED17 Q27024948-8696DB63-B5F5-4D7B-80D4-3DC135C367D8 Q28082782-D1B4307A-6640-4DB9-A32F-C0547E8274B9 Q28552735-B6531AE0-5A16-4375-B3E9-EE51E1AB82A5 Q30249047-0BE71447-BE50-46E7-93E4-F09814C4F7F0 Q33377834-9D6779F0-B218-4805-A7CD-F92E4A49AF37 Q33403679-01069AE7-A853-4A7A-A9C2-0411352A89EC Q33426694-F9021059-CA59-41BA-9115-364E77E03A88 Q33431220-2CBDE616-FF73-4F89-ACF3-C346981B584E Q33433861-8D7D9AAB-954D-481F-8144-2A214A0AA901 Q33565845-23EF105C-FF98-4A7E-9895-A124183A6E1D Q33578564-5DDA0BAF-6A38-44BC-9307-D51C17DFDEAD Q33619249-A189D7F7-86D4-4147-AF12-775C80CCF1A9 Q33621281-5A50A043-7489-439C-A799-DC6448D21E7D Q33793541-2CD70479-9A49-4864-91BF-D7B11CA07784 Q33923405-CAAC1F5C-0DAD-4EDC-8A49-B430EF7288C3 Q34516731-18174810-BF78-446C-80E0-78AA4DE3F518 Q34541463-9B43E3E4-57DF-4121-B7E2-C85A3AE76DE0 Q34567910-694F0A56-352D-47FC-AE7C-C97556A21E4E Q35076184-3539B615-ED35-4527-A815-CB924A43FC20 Q35128721-2B0CC927-B9B1-489C-BF85-63368FA34FD6 Q35227771-0B453FAB-6130-4A99-8FF1-469EC139F68E Q35394211-27325E18-48B6-4F56-9252-C33CD3410644 Q35586693-99E33ECB-47EC-47EC-8A90-44D9847E1FE1 Q35586740-FAEFDC7B-AD60-4619-A57A-EA464E03166D Q35677288-44FD5FC9-BE1E-48F5-8FA7-DB044E126F08 Q35756105-B2F91E64-A8EE-4CFE-85D0-9CE6756BFCB5 Q35823355-2DBD8BB9-F1F0-4EE0-A311-472EA7EAD020 Q36062762-72A69FF3-9320-4C63-8F19-503D35C6F3EA Q36267685-2B7DEC5F-B560-4C36-A2FC-6613751AE63E Q36856612-1E8F1A66-06E5-4AF7-ACB5-58EABC22EF19 Q36947812-C47BAC48-C2B1-4B2A-8224-73E751DC5427 Q36953789-5A2C6C13-FDA3-41BA-8F95-16718BFD3C5A Q36995686-B9050D37-B7C8-4616-8991-3901BE132048 Q37028356-296C5B0C-F534-4009-ACC5-E5953A3E3AC3 Q37038897-2EAFFBD5-AD0E-42D7-A89E-FDF428E5248D Q37172835-0204A1BA-D2D9-4524-9E12-C6D3E2963E4D Q37283592-A4177E1E-0D0C-45E0-BCEA-1763312E068F Q37284023-01F9D348-C188-42CE-885E-CB136DE80441 Q37389950-540A0E85-B725-453A-9E7E-CC4C3F6F64BD

P2860

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

http://www.wikidata.org/entity/Q33371986

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase II study of pemetrexed f ...... cell cancer of the urothelium.

@ast

Phase II study of pemetrexed f ...... cell cancer of the urothelium.

@en

type

label

Phase II study of pemetrexed f ...... cell cancer of the urothelium.

@ast

Phase II study of pemetrexed f ...... cell cancer of the urothelium.

@en

prefLabel

Phase II study of pemetrexed f ...... cell cancer of the urothelium.

@ast

Phase II study of pemetrexed f ...... cell cancer of the urothelium.

@en

P1433

Q33371986-9A2B32A7-3E8F-466A-9D4E-0F4A0F77836D

P1476

Q33371986-47FAE1F9-DD6A-4656-960A-CDD2125D831E

P2093

Q33371986-0D84B526-648D-481A-98EB-97A8243C22D8

Q33371986-2D655001-276B-49DA-9BB0-A977DED21F30

Q33371986-521D4C73-9044-4BB5-9617-3BC363E8FA56

Q33371986-62F73AF9-C1C8-4A11-B0EE-B7313B580C86

Q33371986-65716E46-95BD-4512-8009-D76CDCDAEA4B

Q33371986-74AAB16D-E09A-4402-A68F-1D529A68EB03

Q33371986-A132CB82-5D36-4209-9A1B-E307AC76A521

Q33371986-B27CCD57-4BD9-4BB3-BD5E-AF40F1E15771

Q33371986-B3394BFC-2A27-40DC-99A2-F655565158ED

Q33371986-EEE2F881-03E9-4D1A-BA97-4F70BC5694A4

P304

Q33371986-3D681737-8E39-45F8-B597-68CCA35B7801

P31

Q33371986-26850326-8BE8-4327-853F-AA261F9B6938

P356

Q33371986-0D0EC80D-3EF9-4DE6-A2FB-F38499C9D465

P407

Q33371986-9D5E71C7-7A23-42C8-B991-48CBC929DCE1

P433

Q33371986-26987406-2920-4A67-9589-81629A729B03

P478

Q33371986-44DA6B2C-671E-4483-AB9F-2959C9075C99

P577

Q33371986-7EFA867D-EE52-4F06-87C9-79D8531B4D73

P5875

Q33371986-D95185CD-B798-4CAE-93A8-7488DBEA8064

P698

Q33371986-B2DFEE13-E171-417B-8309-FC0B77198BC6

P356

JCO.2005.03.6699

P1433

Journal of Clinical Oncology

P1476

Phase II study of pemetrexed f ...... cell cancer of the urothelium.

@en

P2093

Bruce J Roth

http://www.w3.org/2001/XMLSchema#string

Christopher J Sweeney

http://www.w3.org/2001/XMLSchema#string

Coleman K Obasaju

http://www.w3.org/2001/XMLSchema#string

David J Vaughn

http://www.w3.org/2001/XMLSchema#string

Donald S Kaufman

http://www.w3.org/2001/XMLSchema#string

Fairooz F Kabbinavar

http://www.w3.org/2001/XMLSchema#string

Michael Arning

http://www.w3.org/2001/XMLSchema#string

Rafael E Curiel

http://www.w3.org/2001/XMLSchema#string

Steven J Nicol

http://www.w3.org/2001/XMLSchema#string

Yanping Wang

http://www.w3.org/2001/XMLSchema#string

P304

3451-3457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.03.6699

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262730472

http://www.w3.org/2001/XMLSchema#string

P698

16849761

http://www.w3.org/2001/XMLSchema#string